Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas, June 03, 2019 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology...
The company will also present at the Jefferies 2019 Global Healthcare Conference MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2019 / Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging...
New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients – G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today presented additional findings from a randomized Phase 2 clinical trial...
Initial experimental treatment arm results from NRG oncology trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today presented monotherapy data from the dose escalation portion of the Phase 1a/1b clinical...
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon-14 skipping mutation Overall response rate among...
Email
Text